BEGIN:VCALENDAR
VERSION:2.0
X-WR-CALNAME;VALUE=TEXT:Fall Symposium | 2017
PRODID:-//Harvard events data//EN
BEGIN:VEVENT
UID:event_1514621_0
SUMMARY:Fall Symposium | 2017
DESCRIPTION:<p>	<strong>DEVELOPING THE FUTURE OF CANCER THERAPEUTICS</strong></p><p>	<strong>INVITED SPEAKERS</strong></p><p>	<strong>Stephanie Dougan, Ph.D.</strong><br>Combination Immunitherapies: Clues from the Microenvironment<br><br><span style="sans-serif"><span style="caret-color:#000000"><strong>Pasi Jänne, M.D., Ph.D.</strong><br><span style="serif">EGFR Mutant Lung Cancer: </span></span></span><span style="caret-color:#000000"><span style="serif">From Clinic to Bench and Back to Clinic</span></span><br><br><span style="sans-serif"><span style="caret-color:#000000"><strong>Jeffrey Karp, Ph.D.</strong></span></span><br><span style="caret-color:#000000"><span style="serif">Towards Accelerated Medical Innovation<br><br><strong>Martin Nowak, Ph.D. </strong><br>The Evolutionary Dynamics of Cancer</span></span><br> </p><p>	<strong>STUDENT SPEAKERS</strong></p><p style="margin:0in-5.85pt0.0001pt0in">	<span style="sans-serif"><span style="caret-color:#000000"><strong>Lara Gechijian, Bradner &amp; Gray Labs</strong></span></span><br><span style="caret-color:#000000"><span style="serif">Targeting TRIM24 for Degradation With a Bromodomain-VHL Ligand Conjugate<br><br><strong>Caitlin Nichols, Beroukhim Lab</strong></span></span><br><span style="sans-serif"><span style="caret-color:#000000"><span style="serif">Loss of Heterozygosity of Essential Genes: </span></span></span><span style="caret-color:#000000"><span style="serif">A Novel Class of Cancer Vulnerabilities</span></span></p><p style="margin:0in-5.85pt0.0001pt0in">	 </p>
LOCATION:NRB 350
STATUS:CONFIRMED
DTSTART:20171108T183000Z
DTEND:20171109T000000Z
END:VEVENT
END:VCALENDAR